knowledge -WSS

knowledge

author：explore 2025-09-03 09:19:04 - browse：2

Illustration of a red human heart with an EKG line in the middle. -- health coverage from STAT — Adobe

Just weeks after Novo Nordisk announced that its obesity drug Wegovy cut the risk of heart complications in a major trial, the company now has results from a different study showing the treatment can also benefit people with a common type of heart failure.

The results, published Friday in the New England Journal of Medicine, found that among people with obesity and heart failure with preserved ejection fraction, or HFpEF, those taking Wegovy experienced greater improvements in symptoms and physical function compared with those on placebo. The improvements were greater than what’s been seen in trials of some other HFpEF treatments.

Novo previously shared topline results in investor calls, but the new study contains the full findings, which are also being presented at the European Society of Cardiology conference this week.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Malaria cases in Florida and Texas: Here’s what you need to know
Next article： At JPM 2024, hospital systems pitch financial strength to investors

WSS

Study suggests new cause of Down syndrome: cells linked to aging

Argenx readies a blockbuster opportunity with drug for autoimmune disease

Future doctors should be trained to promote social change

Gene editing the human germline: What are the risks?

Methadone treatment changes are coming. Do they go far enough?

Medicare Advantage coverage denials need scrutiny, senators say

knowledge

knowledge

hotspot

Drug repurposing or repositioning? The language matters

Leading voice in opioid treatment defends methadone clinic system

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Future doctors should be trained to promote social change

Guidelines to prevent youth baseball injuries need more muscle

Physician assistants need a new name. Here's what it should be

How to save PrEP access — and even expand it

JPM 2024: Biotech’s most prolific dealmaker sees a rosy 2024

Medical records are filled with copy

Mayo Clinic partners with supercomputer AI firm Cerebras at JPM

focus

Health AI adoption puts security, privacy startups on investors' radar

Medicare Advantage overpayments discussion gets experts fired up

A preacher's new calling: Diversifying neuroscience research

Rune Labs, whose app tracks Parkinson's symptoms, raises $12M

Readout Newsletter: Cytokinetics and Novartis' starcrossed tale

Mayo Clinic partners with supercomputer AI firm Cerebras at JPM

knowledge

focus

Wikipedia

hotspot